AAAAAA

   
Results: 1-9 |
Results: 9
Potential new agents in the prophylaxis and treatment of chemotherapy-induced emesis
Authors: Herrstedt, J
Citation: J. Herrstedt, Potential new agents in the prophylaxis and treatment of chemotherapy-induced emesis, EUR J CANC, 37(7), 2001, pp. 823-825
ESMO Minimum Clinical Recommendations - the beginning of a process
Authors: Stahel, R Purkalne, G Herrstedt, J Jelic, S Fervers, B Kloke, O Mellstedt, H Pavlidis, N Jost, L
Citation: R. Stahel et al., ESMO Minimum Clinical Recommendations - the beginning of a process, ANN ONCOL, 12(8), 2001, pp. 1037-1038
ESMO Recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV)
Authors: Herrstedt, J
Citation: J. Herrstedt, ESMO Recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV), ANN ONCOL, 12(8), 2001, pp. 1059-1060
Antiemetic efficacy of combination therapy with granisetron plus prednisolone plus the dopamine D-2 antagonist metopimazine during multiple cycles ofmoderately emetogenic chemotherapy in patients refractory to previous antiemetic therapy
Authors: Sigsgaard, T Herrstedt, J Christensen, P Andersen, O Dombernowsky, P
Citation: T. Sigsgaard et al., Antiemetic efficacy of combination therapy with granisetron plus prednisolone plus the dopamine D-2 antagonist metopimazine during multiple cycles ofmoderately emetogenic chemotherapy in patients refractory to previous antiemetic therapy, SUPP CARE C, 8(3), 2000, pp. 233-237
Prevention and management of mucositis in patients with cancer
Authors: Herrstedt, J
Citation: J. Herrstedt, Prevention and management of mucositis in patients with cancer, INT J ANT A, 16(2), 2000, pp. 161-163
A dose escalating study of topotecan preceding cisplatin in previously untreated patients with small-cell lung cancer
Authors: Sorensen, M Jensen, PB Herrstedt, J Hirsch, FR Hansen, HH
Citation: M. Sorensen et al., A dose escalating study of topotecan preceding cisplatin in previously untreated patients with small-cell lung cancer, ANN ONCOL, 11(7), 2000, pp. 829-835
Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy
Authors: Sigsgaard, T Herrstedt, J Handberg, J Kjaer, M Dombernowsky, P
Citation: T. Sigsgaard et al., Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy, J CL ONCOL, 19(7), 2000, pp. 2091-2097
The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients
Authors: Klastersky, J Paesmans, M Rubenstein, EB Boyer, M Elting, L Feld, R Gallagher, J Herrstedt, J Rapoport, B Rolston, K Talcott, J
Citation: J. Klastersky et al., The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients, J CL ONCOL, 18(16), 2000, pp. 3038-3051
Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy
Authors: Sigsgaard, T Herrstedt, J Andersen, LJ Havsteen, H Langer, SW Kjaerbol, AG Lund, H Kjaer, M Dombernowsky, P
Citation: T. Sigsgaard et al., Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy, BR J CANC, 80(3-4), 1999, pp. 412-418
Risultati: 1-9 |